Clinical Trials Logo

Eczema clinical trials

View clinical trials related to Eczema.

Filter by:

NCT ID: NCT04537468 Completed - Healthy Clinical Trials

Development of a Method to Measure mRNA Levels in Skin Samples

Start date: May 11, 2017
Phase: N/A
Study type: Interventional

The purpose of this study was to develop a non-invasive method to measure mRNA levels using tape stripping on the skin of patients with psoriasis and patients with atopic dermatitis.

NCT ID: NCT04530643 Completed - Atopic Dermatitis Clinical Trials

A Phase II Study of HY209 Gel for Atopic Dermatitis Patients (Shaperon)

Start date: August 26, 2020
Phase: Phase 2
Study type: Interventional

A Randomized, Double-blinded, Placebo-controlled, Parallel, Multi-Center Phase II Clinical Study to Evaluate the Efficacy and Safety of HY209 gel for Patients with Atopic Dermatitis

NCT ID: NCT04510961 Completed - Eczema Clinical Trials

Paraffin Bath Therapy for Chronic Hand Eczema

Start date: January 10, 2019
Phase: N/A
Study type: Interventional

Objective: Chronic Hand eczema (CHE) is a common inflammatory skin disease has a major medical psychological and socio‐economic implications that affect quality of life (QoL)and work ability. This study, the first randomized controlled trial that will be conducted to evaluate the effect of paraffin bath therapy (PBT) in the treatment of CHE.

NCT ID: NCT04504279 Completed - Atopic Dermatitis Clinical Trials

Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis

Start date: October 13, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the potential improvement in atopic dermatitis signs and symptoms following the application of FB-401 in patients 2 years or older with mild to moderate atopic dermatitis. FB-401 will be applied topically for 16 weeks and progress will be assessed by assessment of the skin and patient reports.

NCT ID: NCT04490109 Completed - Atopic Dermatitis Clinical Trials

B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis

Start date: June 4, 2020
Phase: Phase 2
Study type: Interventional

This is a double-blind, randomized, vehicle-controlled study to assess the efficacy, safety, and tolerability of 2 doses of B244 for the treatment of pruritus in adults with a history of atopic dermatitis. Subjects who meet the study entry criteria will be randomized in a 1:1:1 ratio to receive twice daily topical doses of B244 O.D. 5.0, B244 O.D. 20.0, or vehicle (placebo) for 4 weeks.

NCT ID: NCT04472546 Completed - Healthy Clinical Trials

Use of the SpiderMass for in Vivo Analysis of the Skin in Five Chronic Inflammatory Dermatosis

Start date: December 13, 2019
Phase: N/A
Study type: Interventional

The physiological states of the skin are characterized by a certain homeostasis linked to the balance of the metabolic pathways. When these pathways are deregulated, the proteic, lipidic and metabolic is affected. It is thus possible to follow a change in the state of the skin by looking at change in the associated molecular profile. The PRISM laboratory (INSERM U1192) in Lille has developed an innovative system laser called SpiderMass composed of 4 parts: 1. A laser used for the micro-sampling of material in vivo, 2. A transport transfer line of the ablated particles, 3. A mass spectrometer that analyzes them in real time and generates the molecular profiles of the epidermis, 4. A data analysis procedure. The SpiderMass(TM) is of great interest for the study of the skin because it allows non-invasive vivo characterization, and therefore without biopsy or sample preparation. In addition, it will complement techniques already used in the research center such as FTIR spectroscopy. Indeed, in acne studies the FTIR allows to obtain only the Fatty Acid Triglycerid ratio while the SpiderMass permits to detail these lipid classes by each observed molecule on the surface of the skin and follow their evolution.

NCT ID: NCT04471896 Completed - Acne Clinical Trials

Joovvin' for Your Skin Health Study

Start date: August 1, 2020
Phase: N/A
Study type: Interventional

Sixty day single arm trial examining self-report and remote dermatology assessment of cosmetic skin health after daily 10-20 minute sessions with an infrared light therapy device (the Joovv Mini)

NCT ID: NCT04468711 Completed - Atopic Dermatitis Clinical Trials

Vitamin D in Egyptian Children With Atopic Dermatitis

Start date: June 6, 2018
Phase: Phase 3
Study type: Interventional

There is an emergent evidence demonstrating the role of Vitamin D deficiency in eczema. Vitamin D supplementation with standard treatment yielded positive clinical outcomes for children and adolescents with mild and moderate AD; however, the potential benefit of vitamin D in severe cases remains unclear

NCT ID: NCT04447417 Completed - Atopic Dermatitis Clinical Trials

Dupilumab Skin Barrier Function Study in Atopic Dermatitis

BALISTAD
Start date: July 16, 2020
Phase: Phase 4
Study type: Interventional

Primary Objective: - Evaluate changes in skin barrier function with transepidermal water loss (TEWL) assessed after skin tape stripping (STS) in pre-defined lesional skin in participants with moderate to severe atopic dermatitis (AD) treated with dupilumab. Secondary Objectives: - Evaluate changes in skin barrier function with TEWL assessed after STS in pre-defined lesional and non-lesional skin in participants with moderate to severe AD treated with dupilumab in reference to normal skin of healthy volunteers. - Evaluate time course of skin barrier function with TEWL assessed before and after STS in pre-defined lesional and non-lesional skin in participants with moderate to severe AD treated with dupilumab in reference to normal skin of healthy volunteers.

NCT ID: NCT04444752 Completed - Clinical trials for Moderate-to-severe Atopic Dermatitis

A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

Start date: July 17, 2020
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of CBP-201 in adult subjects with moderate to severe atopic dermatitis.